Research on Nimodipine Controlled Release Drug System Based on the Principle of Osmotic Pressure
ZHANG Wen-jun, MA Rui, LI Mu-yao, LIU Si-yi, WANG Li*
School of Pharmaciutical Science, Harbin University of Commerce, Engineering Research Center of Natural Anti-Cancer Drugs, Ministry of Education, Heilongjiang Key Laboratory of Preventive and Therapeutic Drug Research of Senile Diseases, Harbin 150076, China
Abstract：OBJECTIVE To prepare nimodipine osmotic pump capsule based on osmotic pressure principle, and investigate the factors affecting its drug release behavior, prescription optimization and release mechanism. METHODS According to the fitting degree between the cumulative release rate of nimodipine osmotic pump capsule in vitro and the zero-order equation, the types and amounts of auxiliary materials in capsule shell, drug-containing layer and booster layer were investigated by single factor. The main influencing factors of release were pore-forming agent, osmotic pressure active substance and swelling agent.The Box-Behnken design was used to fit the model and determine the best prescription. Three batches of nimodipine osmotic pump capsules were prepared, and their release characteristics were investigated by fitting with the zero-order equation in vitro, and then the release mechanism was studied by similarity factor method (f2). RESULTS In the optimal prescription of nimodipine osmotic pump capsule, the dosage of pore-forming agent (PEG 6000), osmotic pressure active substance (NaCl) and swelling agent (PEG 8000 thousand) were 14 mg, 33.7 mg and 33.2 mg respectively. The drug release is relatively complete within 12 hours, indicating that the porogen is the drug release pathway and the active substance is the drug release power. CONCLUSION The nimodipine osmotic pump capsule prepared has a good controlled release effect.The cumulative release is greater than 90%, and it is close to the zero-order release equation, which is in line with expectations.
张文君, 马蕊, 李沐谣, 刘思怡, 王立. 基于渗透压原理实现尼莫地平可控释药系统的研究[J]. 中国药学杂志, 2022, 57(9): 718-728.
ZHANG Wen-jun, MA Rui, LI Mu-yao, LIU Si-yi, WANG Li. Research on Nimodipine Controlled Release Drug System Based on the Principle of Osmotic Pressure. Chinese Pharmaceutical Journal, 2022, 57(9): 718-728.
WU C, ZHAO Z Z, ZHAO Y, et al. Preparation of a push-pull osmotic pump of felodipine solubilized by mesoporous silica nanoparticles with a core-shell structure[J]. Int J Pharm, 2014, 475(1-2): 298-305.
[2]
YAN W, HU C X, ZHANG Z Q. Preparation and prescription optimization of curcumin solid dispersion monolayer osmotic pump controlled release tablets [J]. Chin Tradit Pat Med(中成药), 2019, 41(8):1768-1773.
[3]
YIN L N, ZHANG Y W, CHEN X X, et al. Preparation and pharmacokinetics of huperzine A micro-porous osmotic pump pellets[J]. Chin Pharm J(中国药学杂志), 2019, 54(9):720-725.
[4]
WANG Z J, LIU Z P, XU Y, et al. Preparation and in vitro evaluation of naringenin self-microemulsion asymmetric membrane osmotic pump capsule [J]. Nat Prod Res Dev(天然产物研究与开发), 2019, 31(7):1271-1277, 1251.
[5]
CHENG X K, SUN M, GAO Y, et al. Design and evaluation of osmotic pump-based controlled release system of ambroxol hydrochloride[J]. Pharm Dev Technol, 2011, 16(4): 392-399.
[6]
REN J G, YANG S, WANG L. Progress of oral osmotic pump preparatio[J]. J Pharm Res (药学研究), 2013, 32(5): 295-297.
[7]
AN X X, ZHOU H L, LI C H, et al. Research progress of oral osmotic pump controlled release preparation [J]. J China Pharm (中国药房), 2018, 29(22): 3165-3168.
[8]
BAI Z Y, SHAO S Y, XU X Y, et al. Application progress of osmotic pump technology in traditional Chinese medicine preparation field [J]. Chin Tradit Herb Drugs (中草药), 2016, 47(9): 1619-1624.
[9]
WANG L, LI M Y, SUN S T, et al. Preparation and release mechanism of salvianolic acid B controlled release capsules based on osmotic pressure principle [J]. Cent South Pharm(中南药学), 2021, 19(2): 198-202.
[10]
ZHOU H, HU R F, JIN D, et al. Research progress of capsule osmotic pump controlled release preparationet [J]. Anhui Med Pharm J (安徽医药), 2017, 21(6): 983-986.
[11]
CARLSON A P, HANGGI D, MACDONALD R L, et al. Nimodipine reappraised: an old drug with a future[J]. Curr Neuro Pharmacol, 2020, 18(1), 65-82.
[12]
MALEK R, MAJ M, WNOROWSKI A, et al. Multi-target 1, 4-dihydropyridines showing calcium channel blockade and antioxidant capacity for Alzheimer′s disease therapy[J]. Bioorg Chem, 2019, 91(10): 1032-1045.
[13]
KAPLAN N, YILMAZ I, KARAARSLAN N, et al. Does nimodipine, a selective calcium channel blocker, impair chondrocyte proliferation or damage extracellular matrix structures[J]. Curr Pharm Biotechnol, 2019, 20(6): 147-154.
[14]
HUANG Y P, ZHANG S S, SHEN H F, et al. Controlled release of the nimodipine-loaded self-microemulsion osmotic pump capsules: development and characterization[J]. AAPS Pharm Sci Tech, 2018, 19(3): 1308-1319.
[15]
WANG T Y, ZHAO Q F, HAN X, et al. Preparation of nimodipinenano-solid dispersion with mesoporous silica [J]. Chin Pharm J(中国药学杂志), 2014, 49(13):1139-1145.
2022, Vol. 57 
